Business Insider1mon
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia. The launch of our non-GLP study in December 2024 marked the ...
Nasdaq1mon
Silo Pharma's SP-26 Shows Promising Initial Safety And Absorption Data For Pain Relief
(RTTNews) - Silo Pharma, Inc. (SILO) on Tuesday announced positive early findings from its ongoing study evaluating the pharmacokinetics, safety, and tolerability of SP-26, a novel ketamine-based ...
Business Insider1mon
Silo Pharma announces initial data from SP-26 study
Silo Pharma (SILO) announced am update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously.
manilatimes1mon
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia. The launch of our non-GLP study in December 2024 marked the first ...